Wellington Management Company and Morningside Ventures joined healthcare investment specialists OrbiMed and Vivo Capital to lead a $100 million Series C round for Gracell Biotechnologies.
"We are very pleased to expand our investor base with support from a high caliber consortium," said Dr. William Wei Cao, founder, chairman, and CEO of Gracell, "Our passion is to bring transformative CAR-T cell therapies to a broader group of patients by developing products that are efficacious and can be made widely available."
Joining fellow existing investor OrbiMed, Temasek Holdings, Lilly Asia Ventures and King Star Med . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.
